124 related articles for article (PubMed ID: 28673584)
1. PARP inhibitors in acute myeloid leukaemia therapy: How a synthetic lethality approach can be a valid therapeutic alternative.
Gafencu GA; Tomuleasa CI; Ghiaur G
Med Hypotheses; 2017 Jul; 104():30-34. PubMed ID: 28673584
[TBL] [Abstract][Full Text] [Related]
2. PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment.
Zhao L; So CW
Exp Hematol; 2016 Oct; 44(10):902-7. PubMed ID: 27473567
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
4. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
Faraoni I; Giansanti M; Voso MT; Lo-Coco F; Graziani G
Biochem Pharmacol; 2019 Sep; 167():133-148. PubMed ID: 31028744
[TBL] [Abstract][Full Text] [Related]
5. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Li X; Li C; Jin J; Wang J; Huang J; Ma Z; Huang X; He X; Zhou Y; Xu Y; Yu M; Huang S; Yan X; Li F; Pan J; Wang Y; Yu Y; Jin J
EBioMedicine; 2018 Dec; 38():47-56. PubMed ID: 30472087
[TBL] [Abstract][Full Text] [Related]
6. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Ferrara F
Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
[TBL] [Abstract][Full Text] [Related]
7. Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi.
Ullah K; Ahmed P; Raza S; Satti TM; Chaudhry QU; Akhtar F; Kamal MK; Akhtar FM; Khan B
J Pak Med Assoc; 2007 Sep; 57(9):434-9. PubMed ID: 18072636
[TBL] [Abstract][Full Text] [Related]
8. Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG).
Wedding U; Bokemeyer C; Meran JG; ; ;
Onkologie; 2004 Feb; 27(1):72-82. PubMed ID: 15007253
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
10. [Combination chemotherapy for acute myeloid leukemia].
Nagai T
Nihon Rinsho; 2009 Oct; 67(10):1921-5. PubMed ID: 19860191
[TBL] [Abstract][Full Text] [Related]
11. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
Tallman MS
Hematology Am Soc Hematol Educ Program; 2005; ():143-50. PubMed ID: 16304372
[TBL] [Abstract][Full Text] [Related]
12. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
Fiedler W; Kayser S; Kebenko M; Janning M; Krauter J; Schittenhelm M; Götze K; Weber D; Göhring G; Teleanu V; Thol F; Heuser M; Döhner K; Ganser A; Döhner H; Schlenk RF
Br J Haematol; 2015 Jun; 169(5):694-700. PubMed ID: 25818407
[TBL] [Abstract][Full Text] [Related]
14. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
15. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
16. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
[TBL] [Abstract][Full Text] [Related]
17. Current treatment of acute myeloid leukemia.
Roboz GJ
Curr Opin Oncol; 2012 Nov; 24(6):711-9. PubMed ID: 23014187
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Poly(ADP-ribose) Polymerase Inhibitor, Pamiparib (BGB-290) in Treating Acute Myeloid Leukemia and the Characterization of Its Nanocarrier.
Xu X; Wang J; Tong T; Lin SF; Liu C; Zhou D
J Biomed Nanotechnol; 2021 Nov; 17(11):2165-2175. PubMed ID: 34906277
[TBL] [Abstract][Full Text] [Related]
19. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.
Quarello P; Fagioli F; Basso G; Putti MC; Berger M; Luciani M; Rizzari C; Menna G; Masetti R; Locatelli F
Br J Haematol; 2015 Nov; 171(4):566-73. PubMed ID: 26223157
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
Devine SM; Owzar K; Blum W; Mulkey F; Stone RM; Hsu JW; Champlin RE; Chen YB; Vij R; Slack J; Soiffer RJ; Larson RA; Shea TC; Hars V; Sibley AB; Giralt S; Carter S; Horowitz MM; Linker C; Alyea EP
J Clin Oncol; 2015 Dec; 33(35):4167-75. PubMed ID: 26527780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
